LB99
Aspirin, non-steroidal anti-inflammatory drug and paracetamol use is associated with an increased risk of prostate cancer in a large, population-based, case-control study
Ali Murad1, Liz Down1, George Davey Smith1, Jenny Donovan1, Janet Athene Lane1, Freddie Hamdy2, David Neal3, Richard Martin1
1University of Bristol, UK; 2John Radcliffe Hospital, Oxford, UK; 3University of Cambridge, UK
Background
Evidence from laboratory studies suggests that chronic inflammation plays an
important role in prostate cancer aetiology. This has resulted in speculation
that non-steroidal anti-inflammatory drugs, such as aspirin and ibuprofen, may
protect against prostate cancer development.
Method
We used data from a case-control study (ncases= 1,016; ncontrols=
5,043), nested within a UK-wide population-based study that used a PSA-testing
approach, to investigate the effect of aspirin, non-steroidal anti-inflammatory
drug and paracetamol use on prostate cancer risk.
Results
We found evidence for an increased risk of PSA-detected prostate cancer amongst
users of aspirin (OR= 1.24, 95% CI= 1.01 to 1.52), non-aspirin non-steroidal
anti-inflammatory drugs (OR= 1.51, 95% CI= 1.13 to 2.01) and overall
non-steroidal anti-inflammatory drugs (OR= 1.37, 95% CI= 1.14 to 1.64).
Paracetamol use was not associated with prostate cancer. Aspirin, non-steroidal
anti-inflammatory drug and paracetamol use were associated with reduced serum
PSA concentrations amongst controls.
Conclusion
Our findings raise doubts about the suitability and safety of using
non-steroidal anti-inflammatory drugs as chemopreventive agents in the primary
prevention of prostate cancer.
